Uniondale, NYNCT07323732Now EnrollingIRB Ready

NSCLC Clinical Trial in Uniondale, NY

Access cutting-edge nsclc treatment through this clinical trial at a research site in Uniondale. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Uniondale location

Preparing your pre-screening questions…

Expert Care in Uniondale

Access nsclc specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related nsclc treatment provided free

Apply for This Uniondale Location

Check if you qualify for this nsclc clinical trial in Uniondale, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Uniondale

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Uniondale site if eligible
  4. 4Begin participation

About This NSCLC Study in Uniondale

The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD).

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. - Patient age ≥ 18 at time of consent
Stage I - II NSCLC (as per the American Joint Commission on Cancer (AJCC) 8th edition) ° Pathologically proven diagnosis of cancer is strongly recommended but is not required if the risk of biopsy is unacceptable. If pathological evidence is not available, there must be clinical evidence for NSCLC and multidisciplinary consensus for treatment.
Interstitial Lung Disease diagnosis (one of the below)
ILD as diagnosed and managed by a pulmonologist
ILD based on diagnostic imaging criteria and abnormal DLCO
ILD as a result of connective tissue diseases (e.g., polymyositis/dermatomyositis, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, mixed connective tissue disease)
ECOG performance status of 0 - 3
Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply:
Women \<50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
Women ≥50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \>1 year ago, had chemotherapy-induced menopause with last menses \>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
Life expectancy of at least 6 months

Exclusion Criteria

Previous thoracic radiation
History of pneumonectomy
Major surgical procedure (e.g. intra-cranial, intra-thoracic, intra-abdominal, or intra-pelvic) within 28 days prior to enrollment.
Severe concurrent illness that may preclude timely completion of thoracic radiation or study procedures
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
ILD exacerbation requiring hospitalization in the last 30 days
Poorly controlled cardiac arrhythmias not responding to medical therapy or a pacemaker
Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential unless they are willing to employ a highly effective non-estrogen based contraception from screening to 30 days after the last dose of BIO 300 or to abstain from sexual intercourse during these time periods.
Effective method of non-estrogen-based contraception: condom and a diaphragm, condom and intrauterine device, condom and Depo-Provera, condom and Nexplanon, or condom and progesterone mini-pill
Women who have been off estrogen contraceptives for a minimum 5 days prior to the first scheduled day of study intervention dosing are eligible.
Concomitant medications:
Any investigational anticancer therapy.
Planned concurrent chemotherapy or immunotherapy
Biologic drugs targeting the immune system (e.g. TNFα blockers, anakinra, rituximab, abatacept, tocilizumab) planned to be use concurrently with BIO 300

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Uniondale?

Yes, this clinical trial (NCT07323732) has an active research site in Uniondale, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

NSCLC Treatment Options in Uniondale, NY

If you're searching for nsclc treatment options in Uniondale, NY, this clinical trial (NCT07323732) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Uniondale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced nsclc specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all nsclc clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Uniondale, NY

See all lung cancer clinical trials recruiting in Uniondale — not just this study.

Browse Lung Cancer Trials in Uniondale →

Browse More Trials by Condition

Lung Cancer TrialsSmall Cell Lung Cancer TrialsNon-Small Cell Lung Cancer TrialsAll Conditions →

Ready to Join in Uniondale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Uniondale, NY